Table 3. Effect of prostacyclin infusion... | American Society of Hematology

Table 3.

Effect of prostacyclin infusion on PHTN in 8 patients with SCD at cardiac or Swan-Ganz catheterization

Patient no.	Before prostacyclin				After prostacyclin				Change in PVR, %
Patient no.	PAm, mm Hg	CO, L/min	PCWP, mm Hg	PVR, dynes/s/cm⁻⁵	PAm, mm Hg	CO, L/min	PCWP, mm Hg	PVR, dynes/s/cm⁻⁵	Change in PVR, %
2	43	9.1	12	253	42	9.9	16	199	−21
6	28	4.8	22	242	27	8.6		114	−53
10	56	6.3	24	404	37	6.4	22	188	−54
11	30	10	17	104	29	12.6	15	89	−15
12	36	8.2	9	293	34	8.5	7	248	−15
14	40	8.1	17	214	24	11.3	10	152	−29
17	43	6.7	15	332	31	8.0	13	179	−46
20	27	4.9	8	326	20	7.2	6	194	−40
Mean	37.9	7.3	15.5	271	30.5	9.1	12.7	170	−34
SD	9.7	1.9	5.7	90	7.1	2.1	5.6	51	16

Patient no.	Before prostacyclin				After prostacyclin				Change in PVR, %
Patient no.	PAm, mm Hg	CO, L/min	PCWP, mm Hg	PVR, dynes/s/cm⁻⁵	PAm, mm Hg	CO, L/min	PCWP, mm Hg	PVR, dynes/s/cm⁻⁵	Change in PVR, %
2	43	9.1	12	253	42	9.9	16	199	−21
6	28	4.8	22	242	27	8.6		114	−53
10	56	6.3	24	404	37	6.4	22	188	−54
11	30	10	17	104	29	12.6	15	89	−15
12	36	8.2	9	293	34	8.5	7	248	−15
14	40	8.1	17	214	24	11.3	10	152	−29
17	43	6.7	15	332	31	8.0	13	179	−46
20	27	4.9	8	326	20	7.2	6	194	−40
Mean	37.9	7.3	15.5	271	30.5	9.1	12.7	170	−34
SD	9.7	1.9	5.7	90	7.1	2.1	5.6	51	16

PVR indicates pulmonary vascular resistance. Other abbreviations are explained in Table 2.